Orient Europharma Co Ltd (4120) — Capital Reinvestment Ratio
Latest as of June 2025:
2.68x
Orient Europharma Co Ltd (4120) has a Capital Reinvestment Ratio of 2.68x as of June 2025, meaning it reinvests 3% of its operating cash flow (NT$33.25 Million) in capital expenditures (NT$89.03 Million). See 4120 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
2.68x
Capex / Operating Cash Flow
Operating Cash Flow
NT$33.25 Million
TWD
Capital Expenditures
NT$89.03 Million
TWD
Data as of
Jun 2025
Most recent filing
Orient Europharma Co Ltd Capital Reinvestment Ratio (2015–2023)
This chart tracks Orient Europharma Co Ltd's Capital Reinvestment Ratio across 8 annual periods.
Annual Capital Reinvestment Ratio for Orient Europharma Co Ltd (2015–2023)
Year-by-year Capital Reinvestment Ratio for Orient Europharma Co Ltd from 2015 to 2023. For live market cap and broader valuation context, see 4120 company net worth.
| Year | Reinvestment Ratio | Operating CF (TWD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2023 | 1.56x | NT$64.67 Million | NT$100.70 Million | ▼ -92.3% |
| 2021 | 20.13x | NT$77.65 Million | NT$1.56 Billion | ▲ +5161.6% |
| 2020 | 0.38x | NT$608.55 Million | NT$232.78 Million | ▼ -30.4% |
| 2019 | 0.55x | NT$227.37 Million | NT$124.98 Million | ▼ -36.9% |
| 2018 | 0.87x | NT$231.31 Million | NT$201.61 Million | ▲ +42.5% |
| 2017 | 0.61x | NT$601.08 Million | NT$367.66 Million | ▼ -69.7% |
| 2016 | 2.02x | NT$111.24 Million | NT$224.81 Million | ▲ +467.0% |
| 2015 | 0.36x | NT$643.97 Million | NT$229.54 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow